Search results
- The PIK3CA mutation is considered an independent negative prognostic factor in advanced breast cancer. It can be detected using tumor tissue or liquid biopsy [ 6 ].
People also ask
Can PIK3CA mutations be detected by liquid biopsy?
Are PIK3CA mutations matched?
Can PIK3CA mutations be detected in ctDNA?
What is the prevalence of PIK3CA mutation?
Can simsen-seq detect PIK3CA mutations in plasma?
What is the limit of detection for PIK3CA mutation?
Nov 9, 2021 · PIK3CA mutations were detected in 48.6% of tissue samples and 47.3% of plasma samples, with identical PIK3CA mutation detected in 24/72 (33.3%) patients both in tissue and plasma.
- PIK3CA mutation enrichment and quantitation from blood and tissue
PIK3CA mutation enrichment combined with triplex dPCR assays...
- PIK3CA mutation enrichment and quantitation from blood and tissue
Oct 13, 2020 · PIK3CA mutation enrichment combined with triplex dPCR assays allowed mutation detection in tissue biopsy and cfDNA samples. By applying the logarithmic regression method, we were also...
- Ieva Keraite, Ieva Keraite, Virginia Alvarez-Garcia, Virginia Alvarez-Garcia, Isaac Garcia-Murillas,...
- 2020
Mar 3, 2023 · PIK3CA mutation detection in tissue and liquid biopsies. PIK3CA mutations were detected in 11,767/33,977 (35%) of tissue biopsies: 8,251 (24%) had only SOLAR1m detected, 2,300 (7%) had only OTHERm detected, and 1,216 (4%) harbored mutations of both types.
- 10.1158/1078-0432.CCR-22-2115
- 2023/03/03
SiMSen-Seq-based detection of PIK3CA mutations in plasma shows advantageous concordance with the tissue analyses. A combination with an untargeted approach for detecting ctDNA fractions may confirm a negative PIK3CA result and enhance the performance of the SiMSen-Seq test.
- Christoph Suppan, Ricarda Graf, Stephan Jahn, Qing Zhou, Eva Valentina Klocker, Rupert Bartsch, Ange...
- 2021
Feb 2, 2022 · PIK3CA mutations were detected in 48.6% (36/74) of archival tumour tissue samples (29 primary, 45 metastatic). In one tumour sample, two PIK3CA mutations were observed (Table 2). VAFs ranged from 4.36 to 72.93% (median 28.64%).
- 10.1038/s41416-021-01601-9
- 2022/02/02
- Br J Cancer. 2022 Feb 1; 126(3): 456-463.
Jun 20, 2020 · The median prevalence of PIK3CA mutation was 36% (range: 13.3% to 61.5%); identified testing approaches more commonly used tissue over liquid biopsies and primarily utilized next-generation sequencing (NGS), polymerase chain reaction (PCR), or Sanger sequencing.
Mar 9, 2018 · We demonstrate consistent detection of PIK3CA H1047R mutant DNA in genomic DNA extracted from frozen breast cancer biopsies, FFPE material or cancer cell lines with a detection sensitivity of...
